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Abstract
Ras is a key regulator of the MAP kinase-signaling cascade and may cause morphologic change of Ras-transformed
cells. Signal transducer and activator of transcription 3 (Stat3) can be activated by cytokine stimulation. In this study,
we unravel that Ha-rasV12 overexpression can downregulate the expression of Stat3 protein at a posttranslational
level in NIH3T3 cells. Furthermore, we demonstrate that Stat3 expression downregulated by Ha-rasV12 overexpres-
sion is through proteosome degradation and not through a mTOR/p70S6K–related signaling pathway. The suppres-
sion of Stat3 accompanied by the morphologic change induced by Ha-rasV12 was through mitogen extracellular
kinase (MEK)/extracellular-regulated kinase (ERK) signaling pathway. Microtubule disruption is involved in Ha-rasV12–
induced morphologic change, which could be reversed by overexpression of Stat3. Taken together, we are the first
to demonstrate that Stat3 protein plays a critical role in Ha-rasV12–induced morphologic change. Oncogenic Ras–trig-
gered morphologic change is through the activation of MEK/ERK to posttranslationally downregulate Stat3 expres-
sion. Our finding may shed light on developing novel therapeutic strategies against Ras-related tumorigenesis.
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Introduction
Ha-, K-, and N-Ras are small G proteins which act as molecular
switches to control signaling pathways that are key regulators of nor-
mal cell growth and malignant transformation [1]. The signaling
pathways downstream of Ras include the Raf/mitogen-activated pro-
tein kinase (MAPK) pathway [2], phosphatidylinositol 3-kinase
(PI3K)/Akt pathway [3], and phospholipase C/protein kinase C
pathway [4]. Ras-transformed fibroblast cells undergo drastic mor-
phologic change probably by decreased focal adhesion or disruption
of the cellular cytoskeleton. Ha-ras overexpression disrupts microtu-
bule formation through ERK activation and has been previously re-
ported [5]. The alteration of actin filaments in Ras-transformed cells
also correlates with decreased expression of various cytoskeletal pro-
teins, such as α-actinin [6], vinculin [7], or the high–molecular weight
tropomyosin isoforms [8,9].
Signal transducer and activator of transcription (STAT) proteins
are cytoplasmic transcription factors that become activated in re-
sponse to growth factors and cytokines. Upon activation, activated
STATs form homo- or heterodimers and are translocated into the nu-
cleus, bind to the promoter region of specific target genes, and reg-
ulate gene transcription [10]. STAT proteins play an important role
in signaling pathways critical to a wide variety of biologic processes,
including cell proliferation, survival, carcinogenesis, differentiation,
and development [11,12].
Cell movement normally accompanies morphologic change. The
role of STATs in cell motility has been reported. Briefly, in Drosophila
ovary, STAT is required for the migration of the border cells [13]. In
zebrafish embryos, signal transducer and activator of transcription 3
(Stat3) is also essential for migration of sheets of cells during gastru-
lation stage [14]. In addition, keratinocytes of Stat3 knockout mouse
exhibit migration defects of wounding ability [15]. Activated Stat3 is
a component of focal adhesion within ovarian cancer cells and mouse
fibroblasts [16]. Together, the above findings raise the possibility that
activated Stat3 may contribute to cell motility by responding to
changes in cell adhesion or by affecting the cytoskeleton. Recently,
it has been reported that Stat3 is required for the stabilization of mi-
crotubules and cell migration [17]. In summary, Stat3 seems essential
for a morphologic change during cell migration and transformation.
In this study, we unravel that Ha-rasV12 overexpression–induced
NIH3T3 morphologic change of cells is through downregulation
of Stat3 protein at a posttranslational level.
Materials and Methods
Materials
The active-form Stat3 (pRcCMV-Stat3C) was kindly provided by
Dr. James Darnell, Jr. [18]. The reporter plasmid of Stat3 promoter
(pST3LUC-2) was described previously [19]. Pharmaceutical inhibitors
PD98059, U0126, LY294002, SB203580, SP600125, and rapamycin
were obtained from Biomol International L.P. (Plymouth Meeting,
PA). MG132 was obtained from Calbiochem (San Diego, CA). Ras
antibody was obtained from Oncogene Science (San Diego, CA). Stat3
antibody was obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). β-Actin antibody was obtained from Sigma-Aldrich (St
Louis, MO). The antibodies for p70S6K1-Thr389, ERK-Thr202/
Tyr204, ERK, Akt-Ser473, Akt, mTOR-Ser2481, and Stat3-Tyr705
were obtained from New England Biolabs (Beverly, MA). Monoclonal
anti–acetylated α-tubulin (6-11B-1) was purchased from Sigma Chem-
ical (St. Louis, MO). Fluorescein-conjugated goat anti-mouse second-
ary antibody was purchased from Chemicon (Hofheim, Germany).
Isopropyl β-d-thiogalactopyranoside (IPTG) was purchased from Invi-
trogen (Boston, MA).
Cell Lines
Mouse fibroblast NIH3T3 cells harboring the inducible Ha-rasV12
oncogene (pSVlacOras) cloned from T24 cell line was designated as
7-4 [20]. The 7-4 derivates, 7-4–ST3 cells, contain active-form Stat3
(pRcCMV-Stat3C). All the cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM; Invitrogen Life Technologies, GIB-
CO, Gaithersburg, MD) supplemented with 10% calf serum
(GIBCO) at 37°C in a 5% CO2 incubator.
Cell Lysis
The cell lysates were prepared as described before [21]. Briefly, the
cells were washed twice with ice-cold PBS and lysed with 200 μl per
10-cm plate of whole-cell extract lysis buffer (50 mM Tris, pH 7.4, 1%
NP-40, 2 mM EDTA, 100 mM NaCl, 10 mM Na orthovanadate,
0.1% SDS, 10 mg/ml leupeptin, 2 mg/ml aprotinin, and 100 mM
phenylmethylsulfonyl fluoride) (protease inhibitors from Roche Ap-
plied Sciences, Indianapolis, IN). Cell lysates were further cleaned using
centrifugation at 14,000 rpm for 10 minutes. Protein concentration
was determined using a Bradford assay (Bio-Rad, Richmond, CA).
Western Blot Analysis
Equal amounts of cell lysates were boiled for 5 minutes with the
sample buffer before separation on an SDS–polyacrylamide gel. The
proteins in the gel were transferred onto a nitrocellulose filter (Milli-
pore, Billerica, MA) in Tris–glycine buffer at 100 V for 1.5 hours using
an electroblotter (Amersham Biosciences Corp., Piscataway, NJ). Mem-
branes were blocked with PBS buffer containing 5% nonfat milk before
incubating with antibodies. The target protein binding the specific an-
tibody was detected by enhanced chemiluminescence according to the
manufacturer’s recommendations (Amersham).
RNA Extraction and Semiquantitative Reverse
Transcription–Polymerase Chain Reaction
Total RNA was extracted using a single-step method with TRIzol
reagent (Invitrogen Corp., Carlsbad, CA). For reverse transcription–
polymerase chain reaction (RT-PCR), first-strand cDNA was synthe-
sized from 0.2 to 1 μg of total RNA with an oligo-dT primer and the
Moloney murine leukemia virus (MMLV) reverse transcriptase (Pro-
mega, Madison, WI). The sequences of PCR primers were as follows:
Stat3 sense primer, 5′-GATGCGACCAACATCCTGGTG-3′; Stat3
antisense primer, 5′-GGACATCGGCAGGTCAATGGT-3′; β-actin
sense primer, 5′-TGG AAT CCT GTG GCA TCC ATG AAA C-3′;
and β-actin antisense primer, 5′-TAA AAC GCA GCT CAG TAA
CAG TCC G-3′. The PCR protocol was conducted with the Stat3
primers at 94°C for 30 seconds, 57°C for 1 minute, and 72°C for
1 minute (30 cycles), followed by 72°C for 10 minutes. The PCR
protocol was performed with the β-actin primer at 94°C for 30 sec-
onds, 55°C for 30 seconds, and 72°C for 1 minute (25 cycles), fol-
lowed by 72°C for 10 minutes.
Luciferase Reporter Assays
Samples of 1 × 105 cells in 35-mm plates in triplicate were trans-
fected with desired plasmid DNA using a cationic liposome (Lipofectin;
GIBCO BRL, Life Technologies, Inc., Grand Island, NY). The plasmids
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of pST3LUC-2 Stat3 reporter gene (0.5 μg) and β-galactosidase (β-gal)
expression vector (0.1 μg) were cotransfected into the cells. The me-
dium was replaced with fresh DMEM 16 hours after transfection. Cells
were then treated with 5 mM IPTG for another 24 hours, and then
harvested. Luciferase and β-gal activities of the cell extracts were then
determined, using the luciferase assay system and β-galactosidase en-
zyme assay system (Promega). Luciferase activity was then normalized
using β-gal activities as the internal control.
Immunofluorescence Assay
7-4 and 7-4–ST3 cells were grown on glass coverslips overnight.
After IPTG treatments, cells were washed with PBS, fixed in 50%
acetone/methanol in cold PBS, and blocked with blocking reagent
(DakoCytomation, Inc., Carpinteria, CA) for 1 hour to block non-
specific binding sites. Cells were then incubated with anti–acetylated
α-tubulin antibody diluted 1:500 in blocking reagent for 1 hour. Cells
were washed with PBS and incubated with fluorescein-conjugated
goat anti-mouse secondary antibody at a 1:100 dilution. The cells
were then mounted and the immunofluorescent images were taken
by a confocal microscope (FV-1000; Olympus, Tokyo, Japan).
Results
Oncogenic Ha-ras Overexpression Suppresses Stat3 Expression
through MEK/ERK Pathway
In this study, the 7-4 cells derived from NIH3T3 cells containing
an inducible Ha-ras oncogene under the regulation of Lac system was
used [22]. Briefly, bacterial lactose repressor system (Lac system) can
regulate the expression of a reporter gene by the binding of lac re-
pressor to a lac operator sequence, which is located between the
TATA box and the transcription staring site of the gene in mamma-
lian cells and mice. The reporter gene can be specifically activated
by the addition of the lactose analogue, IPTG, which binds to the
repressor and disables it from binding to the operator sequence by
conformational change. Initially, the Stat3 protein expression levels in
7-4 cells in the presence or absence of IPTG were evaluated. Figure 1
shows that Ras induction, compared with the control of without IPTG,
gradually suppressed Stat3 expression while the time of induction was
increased. The suppressive effect of Ras on Stat3 expression is also dem-
onstrated in a Ras-dependent fashion (Figure 2, the panels for Stat3 and
Ras). In conclusion, an evident correlation between Ras overexpres-
sion and Stat3 downregulation was demonstrated in the stable
NIH3T3 cell line 7-4.
We then clarified the signaling pathways downstream of Ras
involved in the suppression of Stat3 under Ras-overexpressed condi-
tions. Consistent with other reports, phosphorylation of extracellular-
regulated kinase (ERK), Jun N-terminal kinase (JNK), p38, and Akt
were increased by Ras overexpression in 7-4 cells (Figure 2). Quantified
results show that phosphorylation of ERK is impressive and changes
in phosphorylation of JNK and Akt are subtle. In contrast, the total
protein levels of ERK and Akt were not affected (Figure 2). Pharma-
ceutical inhibitors of specific signaling pathways were used to further
clarify the signaling pathways downstream of Ras that participated in
the suppression of Stat3. Treatment of the Ras-overexpressed cells
with MEK/ERK pathway–specific inhibitors, PD98059 or U0126,
the ERK phosphorylation induced by Ras was inhibited in a dose-
dependent manner (Figure 3, A and B, pERK panel). Those inhibitors
do not inhibit Ras-induced Akt phosphorylation (Figure 3, A and B,
pAkt panel). The level of Stat3 protein expression suppressed by Ras
was gradually restored, whereas the Ras-overexpressed cells were treated
with increasing dosages of PD98059 or U0126 (Figure 3, A and B,
Stat3 panel), indicating that MEK/ERK pathway is involved in Ras-
related suppression of Stat3 expression. Treating the same cells with
the PI3K inhibitor, LY294002, the Ras-induced Akt phosphorylation
was inhibited dose-dependently (Figure 3C, pAkt panel), but the levels
of ERK phosphorylation induction was not affected by LY294002 (Fig-
ure 3C, pERK panel). Moreover, the suppression of Stat3 expression by
Ras could not be restored (Figure 3C, Stat3 panel). The p38 and JNK
pathway inhibitors, SB203580 and SP600125, could not reverse the
Ras-related suppression of Stat3 expression (data not shown). Taken to-
gether, the above results clearly demonstrate that downregulation of
Stat3 by oncogenic Ha-ras is mainly through activation of MEK/
ERK and not PI3K/Akt, p38, or JNK signaling pathways.
mTOR/p70S6K Pathway-Related Translational Control
Does Not Participate in Stat3 Expression By Oncogenic
Ha-ras Overexpression
To determine at what level that the Stat3 expression was down-
regulated by Ras, we analyzed the effects of Ras overexpression on
RNA expression of Stat3 as well as on the Stat3 promoter activity.
We found that the mRNA level of Stat3 was unchanged whether
or not Ras was overexpressed (Figure 4A). Similarly, Ras overexpres-
sion does not affect the activity of the Stat3 promoter reporter gene
(Figure 4B). Altogether, our data indicate that downregulation of
Stat3 protein expression by Ras is not at the transcriptional level.
We then clarified the possibility that downregulation of Stat3 protein
Figure 1. Ha-rasV12 overexpression downregulates protein expression level of Stat3. The 7-4 cells were seeded in 10-cm dishes for
24 hours, and then treated with or without IPTG (5 mM) for 3, 6, 9, 12, 18, and 24 hours, respectively. Cells were harvested and the
lysates were subjected to Western blot analysis to detect Stat3, Ras, and β-actin using specific antibodies against each protein.
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expression by Ras is through mTOR/p70S6K signaling pathway.
mTOR, one of the Ras-downstream molecules, is known to par-
ticipate in the translational control of protein expression. The ac-
tivation of mTOR/p70S6K pathway in Ras-overexpressed 7-4 cells
was investigated. Figure 4C shows that the levels of mTOR and its
downstream p70S6K were dose-dependently increased by oncogenic
Ha-ras. To further study whether the translational control of the sup-
pression of Stat3 expression by Ha-ras oncogene is mediated through
mTOR/p70S6K pathway activation, rapamycin was used to in-
hibit Ras-induced mTOR activation. Figure 4D shows that 7-4 cells
treated with rapamycin inhibited Ras overexpression–induced phos-
phorylation of mTOR and p70S6K (pmTOR and pP70S6K panels).
However, the levels of Stat3 protein expression downregulated by Ras
overexpression cannot be reversed (Stat3 panel), indicating that
mTOR/p70S6K pathway–related translational control of protein ex-
pression is not involved in suppression of Stat3 expression by Ras.
Proteosome Degradation Is Involved in Downregulation
of Stat3 By the Oncogenic Ha-ras
Our data indicate that downregulation of Stat3 protein expression
by Ras is not at transcriptional level and mTOR/p70S6K signaling
pathway is also not involved. Figure 5A shows that protein half life
of Stat3 in 7-4 cells is 21 hours after IPTG treatment. We then clarified
the possibility that downregulation of Stat3 protein expression by Ras is
through proteosome degradation. The 26S proteosome inhibitor,
MG132, was used to inhibit proteosome degradation of Stat3. Fig-
ure 5B shows that Stat3 protein expression downregulated by Ras over-
expression could be reversed by treatment of the Ras-overexpressed cells
with MG132 in a dose-dependent manner. These data clarify that
downregulation of Stat3 protein expression by Ha-ras oncogene was
through 26S proteosome-dependent protein degradation.
Overexpression of Oncogenic Ha-ras–Induced Morphologic
Change Is Reversed By the Inhibitors of MEK/ERK Pathway
Altered cellular morphology is one of the characteristics of cell
transformation [23]. Ras overexpression could induce morphologic
Figure 2. Ha-rasV12 overexpression activates JNK, ERK, and PI3K
pathways. The 7-4 cells that were seeded in 10-cm dishes for
24 hours were treated with different dosages of IPTG as indi-
cated for another 24 hours. Cell lysates harvested were subjected
to Western blot analysis to detect the expression levels of vari-
ous proteins using specific antibodies as indicated. The band’s
phosphorylation intensity of JNK, ERK, and Akt was quantified
by densitometry.
Figure 3. Ha-rasV12 overexpression downregulates Stat3 expression through MEK/ERK pathway. The 7-4 cells were seeded in 10-cm
dishes for 24 hours and then treated with IPTG (5 mM) in the presence or absence of the pharmaceutical inhibitors (A) PD98059, (B)
U0126, or (C) LY294002 for another 24 hours. The cells were harvested and the lysates were subjected to Western blot analysis to
detect various protein expression levels by using specific antibodies as indicated.
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change of mouse NIH3T3 fibroblasts, normal rat kidney (NRK) cells,
as well as human MSU-1.1 cells [24]. Similarly, the morphology of
7-4 cells was altered from flat-like (Figure 6A) to round-up–like (Fig-
ure 6B), whereas Ras was overexpressed. Because MEK/ERK, and not
other signaling pathways, was involved in Ha-ras oncogene–related
downregulation of Stat3, we checked whether the morphologic change
induced by oncogenic Ha-ras could also be reversed by inhibition of
the MEK/ERK signaling pathway. As expected, the cells treated with
either PD98059 or U0126 caused apparent reversion of morphology
from round to flat (Figure 6, C and D). In contrast, SB203580,
SP600125, LY294002, or rapamycin caused no reversion of morphol-
ogy (Figure 6, E–H ). Taken together, Ras overexpression–induced
morphologic change is dependent on MEK/ERK pathway.
Oncogenic Ha-ras–Induced Morphologic Change Is Reversed
By Increasing Stat3 Expression
Because oncogenic Ha-ras–induced morphologic change accompa-
nies downregulation of Stat3, the relationship between morphologic
change and Stat3 downregulation was then investigated. A 7-4 der-
ivate, 7-4–ST3 cell line overexpressing active-form Stat3, was estab-
lished to increase Stat3 protein expression regardless whether Ras was
overexpressed or not (Figure 7A, Stat3 panel and Ras panel). The mor-
phology of 7-4–ST3 cells harboring the constitutively expressed Stat3
becomes much flatter compared to that of 7-4 cells, whereas Ras was
overexpressed in the presence of IPTG (Figure 7B). These findings sus-
tain the notion that Stat3 protein is crucial for Ras-mediated morpho-
logic change in 7-4 cells. To clarify whether overexpression of Stat3
affects the signaling pathways activated by oncogenic Ha-ras, the activ-
ities of the major signaling pathways MAPK and PI3K/Akt down-
stream of Ras were evaluated. Figure 7A shows that activation of
MAPK/ERK and PI3K/Akt signaling pathways by Ras was not affect-
ed by increasing the expression of Stat3 in 7-4–ST3 cells. Our data
clearly demonstrate that Ras-induced morphologic change is associated
with Stat3 expression, and that the reverse of Ras-induced morphologic
change is not through MAPK/ERK and PI3K/Akt signaling pathways.
Oncogenic Ha-ras–Induced Morphologic Change Is Due to the
Disruption of Microtubules and Stat3 Stabilizes Microtubules
It has been reported that Ha-ras overexpression disrupts micro-
tubule formation through ERK activation [5]. Stat3 can stabilize mi-
crotubule through interaction with stathmin [17]. Therefore, it is
intriguing to know whether microtubules are involved in Ras- and
Stat3-related morphologic change. Figure 8 shows that acetylated mi-
crotubule networks were disrupted when Ras was overexpressed in
7-4 cells (Figure 8, E vs F ). Conversely, acetylated microtubule net-
works of 7-4–ST3 cells remained intact although Ras was overexpressed
(Figure 8, G vs H ), suggesting that Ras overexpression–induced mor-
phologic change is due to the disruption of microtubules. In contrast,
Stat3 stabilizes microtubules, therefore causing the reversion of Ras-
induced morphologic change.
Figure 4. Stat3 expression is downregulated by Ha-rasV12 through an mTOR/p70S6K–independent pathway. (A) The 7-4 cells, after seed-
ing for 24 hours, were treated with IPTG (5 mM) for another 24 hours. Cells were harvested and RNA was isolated for RT-PCR analysis of
Stat3 expression. β-Actin was used as the internal control. (B) The Stat3 luciferase reporter gene was transiently transfected into the
cells. Twenty-four hours after transfection, the cells were treated with IPTG (5 mM) for another 24 hours. The cells were then harvested
and the cell lysates were subjected to analysis of luciferase activities using the luciferase assay system. (C) The 7-4 cells were treated
with various concentrations of IPTG for 24 hours. (D) The 7-4 cells, after seeding for 24 hours, were treated with IPTG (5 mM) or com-
bined with different dosages of rapamycin for another 24 hours. Western blot analysis was conducted to detect the expression levels of
Stat3, phosphor-p70S6K, phosphor-mTOR, and Ras using the specific antibodies as indicated.
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Discussion
We found that Ha-rasV12 overexpression in NIH3T3 cells could in-
duce cell morphologic change through downregulation of Stat3, which
is mediated through the MEK/ERK signaling pathway. The suppres-
sion of Stat3 expression by Ras is not at the transcriptional level but
through proteosome degradation. We demonstrate that increasing the
expression level of Stat3 reverses Ha-rasV12 overexpression–induced
morphologic change.
Altered cellular structure, shape, and cytoskeletal organization are
characteristics of cellular transformation [23]. Cytoskeletal change
in tumor cells is crucial for transformation [25]. The mechanisms
of Ras-mediated transformation involve a number of downstream
signaling pathways and activation of Raf/MEK/ERK is sufficient to
transform NIH3T3 fibroblasts [26,27]. We show that PD98059
or U0126 treatment effectively blocked the morphologic change of
Ha-rasV12–overexpressed 7-4 cells (Figure 6). In addition, increasing
Stat3 expression reversed the morphologic change of the Ha-rasV12–
overexpressed 7-4 cells (Figure 7B). Therefore, in Ha-rasV12–transformed
mouse NIH3T3 fibroblast, the morphologic change induced by Ha-
rasV12 is dependent onMEK/ERK–induced suppression of Stat3 expression.
Ras overexpression–induced morphologic change occurred not only
in H-ras–transformed mouse NIH3T3 fibroblast but also in K-ras–
transformed rat NRK cells and human MSU-1.1 fibroblast cells
[24]. In NRK rat fibroblast cells, treating the cells with U0126 could
reverse K-ras–mediated morphologic change by blocking both MEK/
ERK and p70S6K pathways [28]. In the Ha-rasV12–overexpressed
NIH3T3 mouse fibroblast, although rapamycin could inhibit Ha-rasV12
overexpression–induced p70S6K activation (Figure 4D), the morpho-
logic change induced by Ha-rasV12 could not be blocked (Figure 6H ),
suggesting that Ha-rasV12 overexpression–induced morphologic change
Figure 5. Proteosome degradation is involved in the downregula-
tion of Stat3 by Ha-rasV12 overexpression. (A) The 7-4 cells seeded
in 10-cm dishes for 24 hours were treated with or without 5 mM
IPTG for 3, 6, 9, 12, 18, and 24 hours, respectively. Cells were har-
vested and the lysates were subjected to Western blot analysis to
detect Stat3. The band’s intensity was quantified by densitometry.
(B) The 7-4 cells, after IPTG (5 mM) treatment for 24 hours, were
then treated with or without MG132 (20 μM) for 1, 3, and 5 hours,
respectively. Harvested cell lysates were subjected to Western blot
analysis and the expression levels of Stat3, Ras, and β-actin were
detected using Stat3, Ras, and β-actin antibodies, respectively.
Figure 6. Ha-rasV12 overexpression–induced morphologic change is blocked by the inhibitor of MEK/ERK pathway. The 7-4 cells were
seeded in the plate and were (A) left untreated or were treated with (B) IPTG (5 mM) alone or in combination with (C) PD98059, (D)
U0126, (E) SB203580, (F) SP600125, (G) LY294002, or (H) rapamycin for 24 hours. The pictures of cellular morphology were taken under
the light microscope at a magnification of ×100.
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is mTOR/p70S6K–independent in mouse NIH3T3 cells. Taken to-
gether, Ras overexpression–induced morphologic change depends on
different signaling pathways that are cell type–specific.
Increased adhesiveness and fast spreading on the collagen matrix was
found in Stat3-deficient keratinocytes, and deficiency of Stat3 in the
cells leads to the hyperphosphorylation of p130cas [29]. Because focal
adhesion complex proteins, including p130cas, modulate multiple cell
functions, including migration, proliferation, survival, and morphologic
change, these results support our findings that the expression levels
of Stat3 protein are critical for Ha-rasV12 overexpression–induced cell
roundup. Stat3 has been shown to localize in focal adhesions and
function in motility of ovarian cancer cells [16], suggesting the effects
of Stat3 on focal adhesion complex proteins. According to this study,
focal adhesion proteins other than p130cas, which may participate in
Stat3 downregulation–induced morphologic change, are worthy of
further investigation.
In NRK cells, farnesyltransferase inhibitor treatment to inhibit Ras
activity can reverse Ras-induced morphologic change [30]. Suzuki
et al. [30] further demonstrated that blockage of Ras activity affected
microtubule dynamics that is involved in these processes. Lovric
et al. [31] also showed that Raf activation–induced reorganization of
the microtubule network is through the hyperphosphorylation of
stathmin. Recently, Ng et al. [17] found that the expression of Stat3
is required for the stabilization of microtubules and cell migration
through directly interacting with stathmin. Our data also showed
that stabilization of microtubules in the 7-4 cells is disrupted by
Ha-rasV12 overexpression. Moreover, increasing Stat3 expression in
7-4–ST3 cells could restore the microtubules’ stability and morpho-
logic change induced by Ras. Altogether, downregulation of Stat3
may affect the interaction of Stat3 with stathmin in 7-4 cells and
further lead to destabilizing the microtubules. However, whether
MEK/ERK pathway is involved in the interaction between Stat3
and stathmin in Ha-rasV12–overexpressed 7-4 cells needs to be fur-
ther clarified.
Stat3 protein modification including ubiquitination has been re-
ported. In H4IIE rat hepatoma cells, osmolarity could regulate Stat3
protein stability. The hyperosmolarity-accelerated Stat3 degradation
could be prevented by proteosome inhibitors because of a decrease
in Stat3 ubiquitination [32]. Selective degradation of Stat3 by the pro-
teasome was also contributed to growth suppression and apoptosis
of ubiquitin-treated hematopoietic cells [33]. In our studies, protea-
some degradation of Stat3 contributes to the Ha-rasV12 overexpression–
induced morphologic change. Although our current studies provided
evidence that Ha-rasV12 overexpression downregulates Stat3 through
Figure 7. Ha-rasV12 overexpression–induced morphologic change can be reversed by the restoration of Stat3 expression. (A) The 7-4 and
7-4–ST3 cells were seeded in 10-cm dishes for 24 hours, and then treated with 0, 0.5, or 5 mM IPTG for 24 hours. The cells were
harvested and the cell lysates were subjected to Western blot analysis and detected using various antibodies indicated. (B) The 7-4
and 7-4–ST3 cells were seeded in 10-cm dishes for 24 hours, and then treated with IPTG (5 mM) for another 24 hours. The pictures
of cellular morphology were taken under the light microscope at the magnifications of ×100 and ×200, respectively.
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proteosome degradation, it remains to be elucidated how Ha-rasV12
overexpression mediates targeting of Stat3 for degradation by proteasome.
To our knowledge, this is the first report to demonstrate that the
levels of Stat3 expression are downregulated by Ha-ras overexpression,
and we found this effect through proteosome degradation. In this study,
we also found that Ha-rasV12 overexpression–downregulated Stat3 ex-
pression resulted from the activation of MEK/ERK pathway. Moreover,
our data clearly indicate that the expression of Stat3 plays a critical role
in Ha-rasV12–induced morphologic change in NIH3T3 cells.
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